Literature DB >> 9597923

Late outcome of 304 consecutive patients with multiple gland enlargement in primary hyperparathyroidism treated by conservative surgery.

C Proye1, B Carnaille, J L Quievreux, F Combemale, C Oudar, M Lecomte-Houcke.   

Abstract

The aim of this study was to assess the late outcome of patients with primary hyperparathyroidism and multiple gland enlargement (MGE) treated by conservative surgery. MGE in primary hyperparathyroidism is the presence of two or more enlarged glands weighing more than 50 mg. Conservative surgery consists in resecting the grossly enlarged glands without biopsying the normal glands. Some authors have suggested that this approach overlooks minute hyperplasia, leading to late recurrences of hyperparathyroidism; conversely, it may result in the unnecessary resection of grossly enlarged, but not hyperfunctioning, glands. Altogether 1231 patients were operated on for primary hyperparathyroidism between 1966 and 1995. Of these patients, 304 (24.9%) had MGE, including 42 cases of multiple endocrine neoplasia (MEN), 12 familial cases, and 250 seemingly sporadic cases. Two, three, or four glands (or more) were involved in 61.8%, 21.4%, and 16.4% of cases, respectively. During the early postoperative period one patient died and ten were reoperated for persistent hypercalcemia. The pathologic diagnoses were double adenomas (13.5%), hyperplasia (35.8%), association of the two (39.8%), and a normal second gland (10.8%) on light microscopy findings. None of the 30 deaths that occurred during follow-up was related to hyperparathyroidism. Altogether 190 patients (79%) were available for follow-up (average 89.3 months): 90% were normocalcemic, 4.7% hypocalcemic, and 5.2% hypercalcemic. A late iPTH assay was done in 147. PTH was appropriate to the serum calcium level in 84.3% and appropriate to normal calcemia in 91.6% of 132 cases. Conservative surgery is thus an acceptable treatment for MGE in patients with hyperparathyroidism. Few late recurrences occur, for which there are no individual predictive criteria.

Entities:  

Mesh:

Year:  1998        PMID: 9597923     DOI: 10.1007/s002689900430

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  6 in total

1.  Minimally invasive video-assisted parathyroidectomy.

Authors:  K K Hallfeldt; A Trupka; J Gallwas; K Horn
Journal:  Surg Endosc       Date:  2001-03-13       Impact factor: 4.584

2.  Rapid intraoperative parathyroid hormone assay--more than just a comfort measure.

Authors:  F Hanif; J C Coffey; L Romics; K O'Sullivan; F Aftab; H P Redmond
Journal:  World J Surg       Date:  2006-02       Impact factor: 3.352

3.  How long should we follow patients after apparently curative parathyroidectomy?

Authors:  Irene Lou; Courtney Balentine; Samuel Clarkson; David F Schneider; Rebecca S Sippel; Herbert Chen
Journal:  Surgery       Date:  2016-11-15       Impact factor: 3.982

4.  The role of selective venous sampling in patients with non-localized primary hyperparathyroidism.

Authors:  İlhan Gök; Nuri Alper Şahbaz; Cevher Akarsu; Ahmet Cem Dural; Meral Mert; Fatma Aysun Erbahçeci Salık; Barbaros Erhan Çil; Deniz Güzey; Halil Alış
Journal:  Turk J Surg       Date:  2020-06-08

5.  Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT.

Authors:  Jeffrey A Norton; David J Venzon; Marc J Berna; H R Alexander; Douglas L Fraker; Stephen K Libutti; Stephen J Marx; Fathia Gibril; Robert T Jensen
Journal:  Ann Surg       Date:  2008-03       Impact factor: 12.969

6.  Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors.

Authors:  Tetsuhide Ito; Hisato Igarashi; Hirotsugu Uehara; Marc J Berna; Robert T Jensen
Journal:  Medicine (Baltimore)       Date:  2013-05       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.